Project Details
Description
MT2022-36 A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects with Severe Sickle Cell Disease;C Genotype
| Status | Active |
|---|---|
| Effective start/end date | 4/10/23 → 4/30/28 |
Funding
- VERTEX PHARMACEUTICALS INCORPORATED
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.